Welcome! Your Free Demo Awaits

Dear Reader, Your free demo of our new stock forecasting AI is ready. You can click here to access it now. But before you do... it's critical you understand something first. While we're happy to let you try this for free... The real power of this tool comes from full, year-round access. Our AI has learned to forecast the price of 2,384 U.S. stocks, to the penny, days in advance. It was built by a former lieutenant colonel who coded top-secret projects for the U.S. military. And our AI specializes in spotting rapid-fire, quick profit opportunities, week after week. That means by using our AI over and over, our users could have already seen gains like 5% in just 1 day on Tesla, or 25% in 2 days on Carvana – just trading regular shares. No options or anything wild. Our AI has spotted dozens and dozens of quick trades like these in just the last few months alone. And these winners could quickly add up to grow your portfolio hundreds or thousands of percent per year. But the only way to see potential profits like that is to KEEP using the AI, all year long, as a full member. Normally a full subscription costs $499 per year – or even much more... But we’ve established a much better way to access this AI for a fraction of the cost. Click here for all the details – and to see how you could potentially triple your entire portfolio over the next 12 months using our AI. Regards, Keith Kaplan CEO, TradeSmith

866.385.2076 | support@tradesmith.com

©2026 TradeSmith, LLC. All Rights Reserved. You may not reproduce, modify, copy, sell, publish, distribute, display or otherwise use any portion of the content without the prior written consent of TradeSmith. TradeSmith is not registered as an investment adviser and operates under the publishers’ exemption of the Investment Advisers Act of 1940. The investments and strategies discussed in TradeSmith’s content do not constitute personalized investment advice. Any trading or investment decisions you take are in reliance on your own analysis and judgment and not in reliance on TradeSmith. There are risks inherent in investing and past investment performance is not indicative of future results. To unsubscribe or change your email preferences, please click here.

TradeSmith | 1125 N. Charles Street, Baltimore, MD 21201 Terms of Use Privacy Policy

Elon Musk has 200 days to save a $1.75 trillion empire

No extension. No negotiation. A hard federal deadline.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Dear Friend, There is a date on a federal EPA permit that should terrify every SPCX shareholder. January 2, 2027. That’s the day the temporary power keeping Elon Musk’s supercomputer alive gets legally shut off. No extension. No negotiation. A hard federal deadline. If Colossus goes dark, the $45 billion Anthropic contract evaporates. The $1.75 trillion valuation collapses. Musk can’t wait 3-to-5 years for permanent equipment. He has months. He’s mathematically forced to buy his way to the front of the line — through one small company that specializes in speed. Dylan Jovine identified it nine months ago. The stock is still priced like a boring industrial. See the one company Musk can’t build without >> “The Buck Stops Here,” Kelly Maguire Behind the Markets Today’s editorial pick for you Adobe Beats Earnings and Raises Guidance. Why the Stock Is Falling Anyway. Posted On Jun 12, 2026 by Ian Cooper Adobe (NASDAQ: ADBE) just delivered another quarter of impressive growth, beating Wall Street expectations on both earnings and revenue due to surging demand for AI. The company also raised its full-year guidance, a move that would normally send shares higher.  Table of Contents AI Continues to Fuel Abode Growth The Real Story Here Unfortunately, investor enthusiasm quickly faded after the company announced that CFO Dan Durn would be leaving the company, triggering a wave of analyst downgrades. Stifel downgraded Adobe shares to Hold from Buy and significantly reduced its price target to $200. Analysts acknowledged the company’s strong financial performance but suggested that the stock could face challenges as investors digest the CFO transition. Wolfe Research also lowered its rating on Adobe to Peer Perform from Outperform, reflecting a more cautious stance despite the company’s solid operating results. Bernstein also lowered its price target on ADBE to $379 from $447, citing uncertainty over the departure of the CFO.  Meanwhile, Evercore ISI downgraded the stock to Hold from Buy and lowered its price target to $225. The firm pointed to uncertainty surrounding the leadership change. For the second quarter, Adobe reported adjusted earnings of $5.96 per share on revenue of $6.62 billion. Both figures exceeded analyst expectations. Wall Street had been looking for earnings of approximately $5.82 per share on revenue of $6.45 billion. The market’s reaction highlights a growing trend among investors. In today’s environment, strong earnings are often not enough to satisfy Wall Street. Investors increasingly want clear visibility into future leadership, execution, and competitive positioning, particularly for companies operating in fast-moving AI markets. Adobe’s results demonstrated that demand remains healthy, but the CFO announcement created a new variable that analysts felt compelled to address. Musk just raised $75 billion. Guess what he needs to buy. Musk needed batteries - he built the Gigafactory. Needed solar - acquired SolarCity. Needed data - bought Twitter. The pattern is consistent: when a supplier becomes mission-critical, he acquires it. Now, with $75 billion raised in the largest IPO in history, one small power infrastructure company is the critical piece his $2 trillion empire can't run without. Dylan Jovine has the name and ticker. Get the Ticker for Free SPONSORED AI Continues to Fuel Abode Growth In fact, according to CEO Shantanu Narayen in the company’s earnings release, “Adobe delivered record revenue of $6.62 billion in Q2 reflecting strong AI-driven demand across our customer groups.” Even better, thanks to AI demand, the company also raised its full-year outlook. It now expects full-year EPS of between $24.35 and $24.45 on revenue ranging from $26.5 billion to $26.6 billion. The updated guidance came in ahead of many analyst expectations and reinforced the view that AI-related demand continues to support the company’s growth trajectory. Adobe has been aggressively integrating generative AI capabilities across its product portfolio, including Creative Cloud, Acrobat, and Experience Cloud. The company’s Firefly AI models continue to gain adoption among both enterprise and individual customers, allowing users to generate images, edit content, and streamline workflows. These innovations are helping Adobe defend its competitive position while creating new opportunities to monetize AI-powered features. Under normal circumstances, such a combination of strong earnings, record revenue, and increased guidance would likely have pushed the stock higher. Instead, investors focused on a major executive change that introduced uncertainty into the investment story. The good news is that weakness may have created a buy opportunity – especially as the company continues to benefit from an unstoppable AI boom. We also have to remember that Adobe is one of the dominant players in creative software, with millions of users relying on its products for professional design, marketing, video editing, and document management.  The Real Story Here While Wall Street is currently focused on the departure of Adobe’s CFO, the company’s underlying business remains exceptionally strong. Record revenue, an earnings beat, and higher guidance suggest that demand for Adobe’s AI-powered products continues to accelerate. Leadership transitions can create short-term uncertainty, but they do not necessarily change the long-term investment thesis. For investors willing to look beyond the immediate headlines, the recent pullback may present an opportunity to gain exposure to one of the leading beneficiaries of the AI revolution at a more attractive valuation.  The key question for investors is whether the CFO change represents a fundamental shift in strategy or simply a temporary distraction. Based on the company’s latest results, there is little evidence that Adobe’s growth engine is slowing. If AI adoption continues at its current pace, the company appears well-positioned to deliver additional revenue and earnings growth over the coming quarters. © 2026 The Backdoor Bull 33 Southeast 4th Street Boca Raton, FL 33432, United States Unsubscribe Terms of Service

(eBook) Trader Tactics for a Market That Won’t Sit Still

I've traded enough summers to know this one's lying to you. The tape looks calm.  Low volatility, new highs, everybody relaxed.  But calm isn't the same as quiet.   After enough years, you stop watching the market shout and start hearing what it whispers underneath. Right now it's whispering plenty.  Narrowing breadth. Winners getting quietly trimmed. A surface that could crack the second something rattles it.  That's why I said yes to being a part of this summer collaborative Ebook called “The Summer Tape: Trader Tactics for a Market That Won’t Sit Still” { Grab your Free Copy here }.  I don't usually share a page with other traders.  But when I saw the caliber of people involved in this project, I made an exception. I had to. I wanted my strategy alongside traders operating at that level. Ten of us, each handing you one tactic for a market that won't sit still. My piece is in there too. So is a little of everything, from hedging to structure to options. This was written for right now, not for some evergreen shelf. Grab it while the read still holds. [ Get your copy while it's still relevant → ]  Hear what the tape is whispering….. This is a promotion Risk Disclaimer All information is for educational purposes only. Nothing should be considered as a buy or sell recommendation. The risk of loss in trading stocks, commodity futures , forex and options is substantial. Before trading, you should carefully consider your financial position to determine if trading is appropriate. When trading stock, forex, futures or options, it is possible to lose more than the full value of your account. All funds committed should be risk capital. Past performance is not necessarily indicative of future results. This email may is a paid advertisement. It could be for a product or service that is not offered, recommended or endorsed by Pro Trader Strategies and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. Proceed at your own risk. By signing up for our offers you agree to our privacy policy and terms and conditions and be sent ours and other third party offers and promotions in which we get paid for. Opt out at any time

Pro Trader Strategies | 11222 S La Cienega Blvd | Los Angeles, CA 90304 US Unsubscribe | Update Profile | Constant Contact Data Notice

Musk declares war on AI rivals

Don't be blindsided by this  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Read online Editor’s Note: If you want to know which chipmaker could be the next NVIDIA, just ask Jeff Brown. He knows more about AI chips than practically anyone on the planet — Thanks to his senior executive roles at Qualcomm, Juniper Networks, and NXP Semiconductors… And Jeff just uncovered that one tiny chipmaker — 148 times smaller than NVIDIA — is set to provide Musk 5 billion chips in the next two years alone. Click here for the full story or read more below. Dear Reader, Elon Musk just declared war on every AI company on earth. SpaceX and xAI carried out a $1.25 trillion mega-merger… And almost nobody understands the significance. Musk's next move means he no longer needs data centers from Microsoft, Amazon, or Google. And it's about to completely rewrite the rules of AI. Make no mistake: This isn't about competing with OpenAI on chatbots. It's about controlling the backbone of the entire AI economy… And when it's done, the top of the tech leaderboard could look completely different. Today's trillion-dollar giants could be yesterday's news. And one tiny company almost nobody has heard of could be the next NVIDIA. Renowned tech expert and angel investor Jeff Brown has tracked it down… A Musk supplier 148 times smaller than NVIDIA itself, set to ship him 5 billion chips over the next two years. He explains everything in this urgent briefing. Click here to watch it before we take it down. Regards, Lindsey Hough Managing Director, Brownstone Research Featured Content from MarketBeat 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend Written by Nathan Reiff. Article Posted: 6/20/2026. Key Points With the GLP-1 agonist market still growing at a rapid pace, companies outside of the pharma industry are increasingly likely to benefit. Three potentially overlooked beneficiaries of GLP-1s may be TDOC, OLLI, and DXCM. TDOC and DXCM are health care firms providing telehealth services and continuous glucose monitoring devices, respectively, while OLLI is a bargain clothing store. Special Report: Forbes calls this a "golden era" for retirement income (From Investors Alley) The GLP-1 revolution is quietly continuing, even as investor attention has shifted to more timely topics. One of the best ways to access the fast-growing weight loss drug space is through makers like Novo Nordisk (NYSE: NVO) or Eli Lilly (NYSE: LLY), the leading companies behind products such as Ozempic and Zepbound. There are, of course, less direct ways for investors to benefit from the GLP-1 rush as well. The prospect of the market tripling in size in the coming years has enticed a host of other drug developers to pursue their own offerings, and a number of up-and-coming pharma firms may be worth watching—or investors can look at dedicated exchange-traded funds (ETFs) like the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) for a broader view. ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid But the impact of GLP-1 agonists is extending beyond the pharma space, and the companies below could benefit from this trend despite having no direct involvement. GLP-1 Telehealth Business Positioned to Thrive Teladoc Health (NYSE: TDOC) operates a telehealth platform that provides patients with virtual care services related to obesity management and metabolic health, among other services. These areas of Teladoc's business, along with GLP-1 prescription initiation, are growing particularly rapidly. The company makes it as easy as possible for qualified patients to gain access to GLP-1 treatment, which can be a game-changer for those without convenient access to in-person specialists. This has had a real impact on Teladoc's results. In Q1 2026, for instance, the firm beat revenue expectations by about $3 million at $614 million, and adjusted EBITDA of $58 million also came in ahead of guidance. Visit-based care is being enhanced by AI-enabled 24/7 offerings that will likely be a sales and margin driver throughout the rest of this year at least. At the same time, Teladoc is working to right its balance sheet by initiating a multi-step debt reduction process and planning to limit its stock-based compensation to $55 million or less in the coming year. The firm is also building its financial strength with a cash reserve that reached $751 million at the end of the first quarter. This is a welcome change for investors after several consecutive quarters of shaky financial health, as indicated by a TradeSmith health indicator in the red zone. GLP-1 Customers Buying New Wardrobes Might Fuel This Retailer's Growth Discount retailer Ollie's Bargain Outlet (NASDAQ: OLLI) may seem like an unlikely beneficiary of GLP-1 drugs, but stores like this could play an increasingly important role for patients losing weight and needing to buy new clothes. Ollie's is among the most aggressive discount retailers in terms of pricing and could be well-positioned to gain business from GLP-1 patients seeking to replace a large volume of clothes quickly. For Q1 2026, Ollie's reported strong results overall, including sales growth of 14% year over year (YOY) and comparable store sales improvement of 1.7% over the same period. Adjusted earnings per share (EPS) increased by 21% YOY as well, despite headwinds including inflation and higher fuel prices. Ollie's is also expanding rapidly, with 27 new stores opening in the first quarter of the year and a planned 75 new openings in total this year. OLLI stock is a Moderate Buy across Wall Street, based on 14 Buy ratings and three Holds. Shares have fallen by almost 30% year-to-date (YTD) but have about 60% upside potential based on analyst price targets. Glucose Monitoring Devices Could Surge in Popularity Although not a pharma company, health care sector peer DexCom (NASDAQ: DXCM) is a medical device firm that could benefit from the GLP-1 trend because of its continuous glucose monitoring (CGM) tools. CGMs are vital for GLP-1 patients with Type 2 diabetes, making these products a useful companion to GLP-1 treatment in some cases. Care providers may increasingly view CGMs and GLP-1s as a combined solution for patients with diabetes. CGMs have long been associated with insulin treatments, but the rapid expansion of GLP-1s beyond the population of patients with diabetes has the potential to open up monitoring needs for those interested in tracking glucose trends even if they are not also using insulin. DexCom has responded by launching over-the-counter products for a wider patient population. Overall, greater awareness of metabolic health and a growing interest in monitoring glucose levels could mean a surge in business for DexCom. This may contribute to DexCom's strong popularity among analysts: the stock has 22 Buy ratings compared to three Holds and one Sell, alongside 17% predicted upside potential. .   Update your email preferences or unsubscribe here © 2026 Ticker Talk 345 N Reid Place, Suite 620 Sioux Falls, SD 57106, United States Terms of Service

the strategy that likes a nervous market

Most investors dread weeks like last week... Record highs one day, a sharp drop the next, nobody sure what the Fed does next. I look at it a little differently. Because there's one strategy I've leaned on for years that actually does better when the market gets nervous. Selling options. When volatility climbs, the premiums you collect for selling options climb right along with it. So the same uncertainty that has everyone else on edge can hand you bigger income for taking the other side of the trade. Done carefully, it isn't gambling. It's a calm, repeatable way to pull cash out of stocks you already understand. It's also how I've generated around $5k a month in extra income, and I haven't had a losing month following this approach. Options Edge+ gives you the whole system in a box so you can follow it too. The Weekly Options Edge Report with specific trade ideas, real-time alerts when we place a trade, daily market sentiment analysis, the EDGE-ucation Hub to build from the ground up, and the members Discord. It's 15% off through the end of our Summer sale. But, we're closing it down in just 24 hours... So, if you want to copy my system for earning extra income trading options... 👉 Get Options Edge+ at 15% off today and join us inside Have a great night, ​ Mark Roussin, CPA Roussin Financial ​ ​

​Unsubscribe | Update your profile | 30767 Gateway Pl Ste #532, Rancho Mission Viejo, CA 92694

The Easy Money Is Gone.

SpaceX fell 16%. Investors may have found the catch.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

June 22, 2026   |   Listen online   |   Read online Three straight down days. That is what everyone saw. → Wednesday: -5%. → Thursday: -3.6%. → Markets closed Friday for Juneteenth. → Monday: -16.4%. SpaceX closed at $154.60 — its biggest one-day decline since going public and a sharp reversal from last week's peak near $225. The company confirmed its first-ever bond sale Monday morning. Many investors immediately pointed to the debt offering as the reason for the selloff. But the bond is only part of the story. The bigger story is what happens next. More specifically: who gets to sell, when they get to sell, and how many shares could suddenly become available. Here is the story. ⇩ SPONSOR BREAK presented by MarketWise* Why SpaceX Just Triggered the End of the Bull Market SpaceX insiders are getting ready to dump as much as $1.6 trillion in paper wealth – the biggest cashout in market history. The same thing happened in 1999 right before the dot-com crash... and now, it's happening again. To see where to move your money before the Melt Up reaches its dramatic conclusion, click here while there's still time.   The Bond Is Now Confirmed SpaceX filed officially Monday morning confirming its first-ever bond sale. The filing itself did not disclose a size, but Bloomberg's reporting from last week — at least $20 billion — remains the working number. Proceeds will repay in full the bridge loan SpaceX took out in February to fund the xAI acquisition, plus related fees. Bank of America, Citigroup, JPMorgan, Goldman Sachs, and Morgan Stanley — the same five banks that ran the IPO — are expected to run this deal too. Debt offerings can pressure a freshly public stock simply because they exist — investors start asking questions about interest expense and why a company needs more outside funding so soon. But the bond by itself does not explain a three-day collapse from $225 to $154.60 — wiping out most of the post-IPO gain in less than a week. The real explanation is the calendar. SPONSOR BREAK presented by MarketWise* "Sell This, Buy That." It's a way to rid yourself of overpriced AI stocks before the tech trade breaks down this summer... And instead move that money into smaller, lesser-known names that are showing real potential to dethrone the "Mag 7".  I even give away a Hotlist and Hitlist of buy and sell ideas that you can act on right now.  Like my recommendation I call "an upgrade to Tesla stock." It's a little-known company that just inked a groundbreaking partnership with the king of AI, Nvidia. This deal virtually hands this under-the-radar firm the keys to the self-driving industries' biggest customers, putting them miles ahead of Tesla in the autonomous vehicle race. That's why I want to put this stock on your radar before markets open.  You can get the name and ticker symbol here.  Marc Chaikin The Calendar. Insiders can sell up to 44% of SpaceX by early September. The float could grow 900%. 22V Research strategist Jeff Jacobson laid out the actual lockup schedule — and once you see it, the last three days make a lot more sense. Today only about 4.2% of SpaceX shares are freely tradeable. That scarcity helped fuel the IPO rally. The problem is that scarcity doesn't last forever. That means up to 44% of shares could become eligible for sale by early September. For context: Today's float is approximately 4.2%. The available share supply could increase by roughly 900%. SPONSOR BREAK presented by Paradigm* “Trump’s Gold Mine” to Deliver 10X Gains In a Few Months   According to Jim Rickards – the world’s #1 gold expert and a man with close ties to Donald Trump’s “inner circle”… The president is about to unleash a major new gold initiative…   One that opens up the largest gold deposit in the entire world – right here on U.S. soil…   And that is valued at over $1 TRILLION.   Today, Jim has revealed one of his favorite ways to play this gold boom – 100% FREE.   Click here to get Jim’s FREE gold pick NOW. The Bull Case Has One Challenge Many bulls have pointed to upcoming Nasdaq and MSCI inclusion as a powerful source of future buying. That argument still has merit. But Jacobson highlights an important catch. The index providers will initially weight SpaceX based on its free float — not its full market capitalization. That means the passive buying may be smaller than many investors expect. At the same time insider selling pressure could be growing. That combination helps explain why investors suddenly became more cautious. The Most Honest Rating Yet → KeyBanc initiated coverage with a Sector Weight rating. Neither bullish nor bearish. Analyst Michael Leshock summarized the situation well: "We see many high-growth avenues over the long term, though risk/reward appears balanced in the near term." After a week of extreme opinions, that may be the most realistic assessment so far. → Strong long-term opportunities. → Plenty of short-term uncertainty. SPONSOR BREAK presented by Brownstone* Live demo of Elon Musk's AI agent Have you tried Elon Musk's new AI agent? It's the most powerful AI ever created. Musk himself thinks it could make investors 70 times their money. In a few short years… I expect an announcement from Musk by the end of this month… That will make this AI agent available to every American. But you can get in right now… When you click this link, I'll give you a live demo of this amazing AI agent – for free. Even The Good News Didn't Work… The whole sector got hit. Rocket Lab joined the Nasdaq 100 today. Normally that would be a celebration. Instead, the stock fell. That may be the clearest sign that Monday wasn't just about SpaceX. The entire sector was under pressure. Rocket Lab had: → A $2.2 billion backlog → 64% revenue growth → Nasdaq 100 inclusion Yet sellers still won. Sometimes market sentiment overwhelms company-specific news. That appears to be what happened Monday. Greenspan's Lesson Alan Greenspan died today at age 100. Most investors remember him for two words: "Irrational exuberance." Those words became synonymous with the dot-com bubble. What many people forget is what happened next. Greenspan made the comment in December 1996. And… the Nasdaq rallied for more than three additional years. Yahoo Finance compared today's AI-driven market with the dot-com era. That is the lesson. Markets can stay enthusiastic much longer than most investors expect. And sometimes the hardest part is recognizing the difference between a warning and a prediction. The Market Trades Expectations Nothing has changed yet at SpaceX. 1\ The insider shares have not been sold. 2\ The float has not expanded. 3\ September is still months away. Yet the stock fell sharply because investors are already thinking about what those future events could mean. If traders believe millions of new shares could hit the market in a few months, some will sell today rather than wait for it to happen. That doesn't mean they are right. It doesn't mean the stock can't recover. It simply means the market is constantly trying to stay one step ahead. The lesson: By the time the event arrives, the market may have already spent weeks reacting to it. Don’t forget to to cast your vote 👇 Poll of the day: Which piece of "dad advice" ages best? → Patience pays → Don't spend what you don't have → If it sounds too good to be true, it is → Focus on what you can control Lesson Of The Day: Was this email forwarded to you? Don’t miss out on future stories — subscribe using the button below. Also, help your friends blossom this spring! Share us with them. Subscribe Share the newsletter 💬 We Want To Hear Your Story: Got a market or stock you want us to analyze next? Just drop your request in the comments here. P.S. - If you no longer want to receive occasional emails from us and you want to unsubscribe, click here 👉 “Unsubscribe” . Thank you! Disclaimer: This letter is not offering investment, trading, or investment advice nor is based on any individual portfolio or business operation. We are not a registered investment, stock nor commodity advisor. One should consult with their own registered advisor to discuss investment strategies that are appropriate for their business or personal goals, risk tolerance and financial situation. Information in this report and on any website is derived from a variety of source believed to be reliable however no representation is made that the information is accurate, complete or correct. These lessons, newsletter and site content is not intended nor shall not constitute or be construed as an offer or recommendation to “buy”, “sell”, “trade” or invest in any securities, commodities, futures, options or other asset referred to in said lessons, reports or newsletters. Rather, this research is intended to identify situations and circumstances that those in the trading community should be aware of to better help assess and improve their own risk management skills. This publication is for informational and educational purposes only. It does not constitute investment, trading, or financial advice and is not based on any individual’s financial circumstances, goals, or risk tolerance. We are not registered investment, stock, or commodity advisors. Always consult a licensed financial professional before making investment decisions. Information provided in this newsletter (and on any affiliated website) is obtained from sources believed to be reliable; however, accuracy and completeness cannot be guaranteed. Opinions expressed are those of the authors and are subject to change without notice. From time to time, this publication may include sponsored content, affiliate links, or advertisements. Such inclusions do not constitute endorsements, and any compensation received does not influence the analysis or opinions presented. TradingLessons is not affiliated with, nor does it verify or guarantee the claims, products, or services of any sponsor or advertiser. Readers should perform their own due diligence before engaging with any advertised offerings. Nothing herein should be interpreted as an offer, recommendation, or solicitation to buy, sell, or trade any security, commodity, derivative, or other financial instrument. This content is intended solely to highlight market developments and educational insights to help readers enhance their understanding of trading and risk management. Update your email preferences or unsubscribe here © 2026 Trading Lessons® 141 W. Jackson Blvd Chicago, IL 60604, United States Terms of Service